2020
DOI: 10.1016/j.jhepr.2019.11.006
|View full text |Cite
|
Sign up to set email alerts
|

Liver fibrosis and CD206+ macrophage accumulation are suppressed by anti-GM-CSF therapy

Abstract: Highlights GM-CSF and TNFa producing CD206 + macrophages accumulate in human fibrotic liver Serum GM-CSF is increased in HCV + patients with higher liver fibrosis GM-CSF drives monocyte to CD206 + macrophage conversion Anti-GM-CSF therapy suppresses liver fibrosis and CD206 + macrophage accumulation Lay summary Liver fibrosis is a major driver of liver disease progression. Herein, we have shown that granulocytemacrophage colony-stimulating factor (GM-CSF) plays an important role in the development of liver fib… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

4
44
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 46 publications
(48 citation statements)
references
References 62 publications
4
44
0
Order By: Relevance
“…The NP models that have been put forward to explain the b → s + − anomalies fall into two categories. Most of the analyses so far have focused on the case where the b → s + − transition receives a contribution from a tree level exchange of a new heavy vector boson, Z , with flavor violating couplings to b and s quarks, as well as couplings to either electrons [23] or muons [24][25][26][27][28][29][30][31][32][33][34][35][36][37] (in the case of Ref. [38] the latter is generated at loop level), or through tree level exchange of leptoquarks [39][40][41][42][43][44].…”
mentioning
confidence: 99%
“…The NP models that have been put forward to explain the b → s + − anomalies fall into two categories. Most of the analyses so far have focused on the case where the b → s + − transition receives a contribution from a tree level exchange of a new heavy vector boson, Z , with flavor violating couplings to b and s quarks, as well as couplings to either electrons [23] or muons [24][25][26][27][28][29][30][31][32][33][34][35][36][37] (in the case of Ref. [38] the latter is generated at loop level), or through tree level exchange of leptoquarks [39][40][41][42][43][44].…”
mentioning
confidence: 99%
“…GM-CSF belongs to the CSF superfamily of growth factors and has been extensively studied in the context of autoimmune diseases. Tan Garcia et al 4 now demonstrate that GM-CSF is overproduced in the blood and the liver of patients with HBV or HCV by CD14+CD206+TNFaproducing macrophages, and that the number of these GMCSFproducing macrophages is positively correlated with fibrosis stage; similar findings are obtained in an animal model of HBV-infected humanized mice. Most importantly, administration of a neutralizing anti-GM-CSF antibody for 4 weeks starting 6 weeks after infection not only reduces the frequency of CD206+ macrophages but also decreases fibrosis.…”
mentioning
confidence: 59%
“…These data are reinforced by the use of mice with global deletion of Ccl24, with similar results, and in vitro data showing a direct effect of CCL24 on the fibrogenic phenotype of hepatic stellate cells. Strikingly, animals with either pharmacological inhibition or genetic invalidation of CCL24 also show reduced hepatocyte injury, suggesting that the antifibrogenic effects are, at least in part, secondary to protective effects against hepatocyte damage, Another aspect highlighted in another paper by Tan Garcia et al 4 relates to the role of granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF belongs to the CSF superfamily of growth factors and has been extensively studied in the context of autoimmune diseases.…”
mentioning
confidence: 99%
“…The Vectra system is the most widely adopted mIHC/IF system currently with several notable publications [4, 72, 5, 3, 29, 73, 81, 82] over the past half a decade worldwide. Some institutions and hospitals even utilize this technology as part of their clinical laboratory tests to help clinicians in their clinical decision making and treatment plans.…”
Section: Brightfield‐based Mihc/ifmentioning
confidence: 99%